STOCK TITAN

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of Peel Hunt as its Joint UK Corporate Broker. The firm will work alongside existing broker UBS to provide corporate broking services.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) ha annunciato la nomina di Peel Hunt come suo Joint Corporate Broker nel Regno Unito. La società lavorerà insieme al broker esistente UBS per fornire servizi di corporate broking.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) ha anunciado el nombramiento de Peel Hunt como su Joint Corporate Broker en el Reino Unido. La firma trabajará junto al broker existente UBS para proporcionar servicios de corretaje corporativo.

PureTech Health (Nasdaq: PRTC, LSE: PRTC)가 Peel Hunt를 영국의 공동 기업 브로커로 임명했다고 발표했습니다. 이 회사는 기존 브로커 UBS와 함께 기업 브로킹 서비스를 제공할 것입니다.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) a annoncé la nomination de Peel Hunt en tant que Joint Corporate Broker au Royaume-Uni. La société travaillera aux côtés du courtier existant UBS pour fournir des services de courtage d'entreprise.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) hat die Ernennung von Peel Hunt zu seinem gemeinsamen Corporate Broker im Vereinigten Königreich bekannt gegeben. Die Firma wird zusammen mit dem bestehenden Broker UBS Corporate-Broking-Dienstleistungen anbieten.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS.

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

Source: PureTech Health plc

FAQ

What is the significance of PureTech (PRTC) appointing Peel Hunt as joint broker?

Peel Hunt's appointment as joint broker alongside UBS enhances PureTech's corporate broking coverage in the UK market.

Who are PureTech's current corporate brokers after the new appointment?

PureTech now has two corporate brokers: Peel Hunt and UBS.

On which stock exchanges is PureTech (PRTC) listed?

PureTech is dual-listed on the Nasdaq and London Stock Exchange (LSE) under the ticker PRTC.

What role will Peel Hunt serve for PureTech (PRTC)?

Peel Hunt will serve as a Joint UK Corporate Broker, providing corporate broking services alongside UBS.
Puretech Health

NASDAQ:PRTC

PRTC Rankings

PRTC Latest News

PRTC Stock Data

400.52M
23.94M
1.56%
0.09%
Biotechnology
Healthcare
Link
United States
Boston